• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

March 20, 2015
CenterWatch Staff

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

Innovent will lead the development and manufacturing for the China market, while Eli Lilly will be responsible for commercialization of the three potential medicines. Innovent also has co-promotion rights.

Eli Lilly will contribute its cMet monoclonal antibody gene for possible treatment of non-small cell lung cancer.

Separately, Eli Lilly will continue the development of its cMet monoclonal antibody program outside of China. Innovent will contribute its monoclonal antibody targeting protein CD-20 for investigation in hematologic malignancies. Innovent has received IND approval in China to begin phase I development of this potential therapy.

Innovent will contribute a preclinical immuno-oncology molecule for development in China. The companies have agreed that Eli Lilly will be responsible for development, manufacturing and commercialization of this molecule outside of China. Eli Lilly also will receive rights to develop and commercialize up to three preclinical bispecific immuno-oncology molecules outside of China.

Innovent will receive a total upfront payment of $56 million. Eli Lilly also could issue future payments exceeding $400 million for the preclinical immuno-oncology molecule if the product reaches certain development, regulatory and sales milestones. Sales royalties and other payments would occur on certain products if commercialized. Further financial terms have not been disclosed.

Eli Lilly and Hanmi Pharmaceutical, a Korea-based global pharmaceutical company, have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, similar requirements outside the U.S., and other customary closing conditions. 

This small molecule is ready to enter phase II and the parties plan to investigate the molecule for the potential treatment of rheumatoid arthritis, lupus, lupus nephritis, Sjögren's syndrome and other related conditions.

"HM71224 is a potent and effective BTK inhibitor and has successfully demonstrated proof-of-mechanism in preclinical studies and a phase I study in Europe," said Dr. Gwan Sun Lee, CEO/president of Hanmi Pharmaceutical.

Eli Lilly will receive worldwide rights to the molecule for all indications excluding China, Hong Kong, Taiwan and Korea. Eli Lilly will take development, regulatory, manufacturing and commercial leadership for the molecule in the Eli Lilly territories. Hanmi will receive an initial payment of $50 million and is eligible for up to $640 million in potential development, regulatory, and sales milestones. If the BTK inhibitor is successfully commercialized, Hanmi would also be eligible for tiered double-digit royalty payments.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing